Sm 14

Drug Profile

Sm 14

Alternative Names: Anti-schistosomiasis vaccine; rSm14; Sm-14; Sm14 vaccine; Snail fever vaccine

Latest Information Update: 01 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oswaldo Cruz Foundation
  • Developer Orygen Biotecnologia; Oswaldo Cruz Foundation
  • Class Parasitic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Schistosomiasis

Most Recent Events

  • 31 Jan 2017 Oswaldo Cruz Foundation and Orygen Biotecnologia complete enrolment in the phase II trial for Schistosomiasis in Senegal (NCT03041766)
  • 06 Dec 2016 Phase-II clinical trials in Schistosomiasis (In volunteers, Treatment-experienced) in Senegal (IM) (NCT03041766)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top